$CRDF
Cardiff Oncology, Inc.

2020 Q4 Form 10-Q Financial Statement

#000162828020015726 Filed on November 05, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q4
Revenue $120.0K $136.0K $90.00K
YoY Change 33.33% 163.12% 12.5%
Cost Of Revenue $0.00
YoY Change
Gross Profit $90.00K
YoY Change 12.5%
Gross Profit Margin 100.0%
Selling, General & Admin $3.420M $1.644M $1.520M
YoY Change 125.0% 14.14% -9.52%
% of Gross Profit 1688.89%
Research & Development $3.200M $2.855M $2.860M
YoY Change 11.89% 1.28% 14.4%
% of Gross Profit 3177.78%
Depreciation & Amortization $120.0K $120.0K $360.0K
YoY Change -66.67% 200.0% 125.0%
% of Gross Profit 400.0%
Operating Expenses $6.620M $4.499M $4.380M
YoY Change 51.14% 5.63% 4.78%
Operating Profit -$4.363M -$4.290M
YoY Change 3.7% 4.63%
Interest Expense -$70.00K -$130.0K $50.00K
YoY Change -240.0% -54.55%
% of Operating Profit
Other Income/Expense, Net -$30.00K -$6.000K $0.00
YoY Change 443.97% -100.0%
Pretax Income -$6.600M -$4.500M -$4.240M
YoY Change 55.66% 8.7% 1.92%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$6.600M -$4.497M -$4.240M
YoY Change 55.66% 8.58% 1.92%
Net Earnings / Revenue -5500.0% -3306.62% -4711.11%
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$185.0K -$0.19 -$485.7K
COMMON SHARES
Basic Shares Outstanding 35.32M shares 23.34M shares 7.742M shares
Diluted Shares Outstanding 23.34M shares

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $131.0M $36.40M $10.20M
YoY Change 1184.31% 304.44% -11.3%
Cash & Equivalents $131.0M $36.40M $10.20M
Short-Term Investments
Other Short-Term Assets $2.100M $1.600M $1.000M
YoY Change 110.0% 100.0% -9.09%
Inventory
Prepaid Expenses $2.055M $1.579M $955.0K
Receivables $320.0K $204.4K $203.5K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $133.4M $38.19M $11.35M
YoY Change 1074.56% 282.78% -11.06%
LONG-TERM ASSETS
Property, Plant & Equipment $624.0K $682.9K $877.8K
YoY Change -28.92% 151.61% -32.7%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $404.0K $155.8K $157.6K
YoY Change 156.38% -8.88% 53.29%
Total Long-Term Assets $1.371M $1.262M $1.733M
YoY Change -20.88% -35.15% 23.14%
TOTAL ASSETS
Total Short-Term Assets $133.4M $38.19M $11.35M
Total Long-Term Assets $1.371M $1.262M $1.733M
Total Assets $134.7M $39.45M $13.09M
YoY Change 929.51% 230.89% -7.66%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.366M $610.2K $656.3K
YoY Change 108.14% 23.94% -1.28%
Accrued Expenses $3.851M $3.643M $3.260M
YoY Change 18.13% 28.19% 83.99%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $300.0K $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $6.119M $5.442M $4.782M
YoY Change 27.97% 30.48% 63.57%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $156.0K $88.45K $128.4K
YoY Change 21.53% -91.96% 205.64%
Total Long-Term Liabilities $156.0K $88.45K $128.4K
YoY Change 21.53% -91.96% 205.64%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.119M $5.442M $4.782M
Total Long-Term Liabilities $156.0K $88.45K $128.4K
Total Liabilities $6.569M $5.928M $5.775M
YoY Change 13.74% 12.56% 41.26%
SHAREHOLDERS EQUITY
Retained Earnings -$231.5M -$224.9M -$208.9M
YoY Change 10.82% 9.89% 8.69%
Common Stock $4.000K $10.08K $8.312K
YoY Change -51.88% 24.52% 7.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $128.2M $33.52M $7.312M
YoY Change
Total Liabilities & Shareholders Equity $134.7M $39.45M $13.09M
YoY Change 929.51% 230.89% -7.66%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q4
OPERATING ACTIVITIES
Net Income -$6.600M -$4.497M -$4.240M
YoY Change 55.66% 8.58% 1.92%
Depreciation, Depletion And Amortization $120.0K $120.0K $360.0K
YoY Change -66.67% 200.0% 125.0%
Cash From Operating Activities -$5.120M -$3.520M -$3.280M
YoY Change 56.1% 10.34% -9.14%
INVESTING ACTIVITIES
Capital Expenditures -$60.00K -$150.0K $0.00
YoY Change 150.0%
Acquisitions
YoY Change
Other Investing Activities $0.00
YoY Change
Cash From Investing Activities -$60.00K -$150.0K $0.00
YoY Change 150.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 99.76M 12.32M 4.440M
YoY Change 2146.85% 726.85%
NET CHANGE
Cash From Operating Activities -5.120M -3.520M -3.280M
Cash From Investing Activities -60.00K -150.0K 0.000
Cash From Financing Activities 99.76M 12.32M 4.440M
Net Change In Cash 94.58M 8.650M 1.160M
YoY Change 8053.45% -591.48% -132.13%
FREE CASH FLOW
Cash From Operating Activities -$5.120M -$3.520M -$3.280M
Capital Expenditures -$60.00K -$150.0K $0.00
Free Cash Flow -$5.060M -$3.370M -$3.280M
YoY Change 54.27% 7.67% -9.14%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001213037
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35558
dei Entity Registrant Name
EntityRegistrantName
CARDIFF ONCOLOGY, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
27-2004382
dei Entity Address Address Line1
EntityAddressAddressLine1
11055 Flintkote Avenue
dei Entity Address City Or Town
EntityAddressCityOrTown
San Diego
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
92121
dei City Area Code
CityAreaCode
858
dei Local Phone Number
LocalPhoneNumber
952-7570
dei Security12b Title
Security12bTitle
Common Stock
dei Trading Symbol
TradingSymbol
CRDF
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
35324607 shares
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36405432 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
10195292 USD
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
204366 USD
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
203480 USD
CY2020Q3 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1578859 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
954957 USD
CY2020Q3 us-gaap Assets Current
AssetsCurrent
38188657 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
11353729 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
682859 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
877823 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
423163 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
697418 USD
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
155770 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
157576 USD
CY2020Q3 us-gaap Assets
Assets
39450449 USD
CY2019Q4 us-gaap Assets
Assets
13086546 USD
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
610236 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
656304 USD
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3643300 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3260061 USD
CY2020Q3 us-gaap Notes Payable Current
NotesPayableCurrent
305000 USD
CY2019Q4 us-gaap Notes Payable Current
NotesPayableCurrent
0 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
883534 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
865379 USD
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
5442070 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4781744 USD
CY2020Q3 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
190199 USD
CY2019Q4 us-gaap Derivative Liabilities Noncurrent
DerivativeLiabilitiesNoncurrent
4127 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
207178 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
860963 USD
CY2020Q3 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
88452 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
128368 USD
CY2020Q3 us-gaap Liabilities
Liabilities
5927899 USD
CY2019Q4 us-gaap Liabilities
Liabilities
5775202 USD
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
20000000 shares
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
926 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
60 USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000 shares
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
26285743 shares
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
26285743 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
8593633 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
8593633 shares
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
10081 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
8312 USD
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
260807295 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
217172528 USD
CY2020Q3 crdf Servicereceivable
Servicereceivable
2403580 USD
CY2019Q4 crdf Servicereceivable
Servicereceivable
971673 USD
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-224892172 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-208897883 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
33522550 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7311344 USD
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
39450449 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
13086546 USD
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
136401 USD
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
51687 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
246738 USD
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
150560 USD
CY2020Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 USD
CY2019Q3 us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 USD
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
0 USD
us-gaap Revenue Not From Contract With Customer
RevenueNotFromContractWithCustomer
1495 USD
CY2020Q3 us-gaap Revenues
Revenues
136401 USD
CY2019Q3 us-gaap Revenues
Revenues
51687 USD
us-gaap Revenues
Revenues
246738 USD
us-gaap Revenues
Revenues
152055 USD
CY2020Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2854812 USD
CY2019Q3 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
2818824 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8036225 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
8297763 USD
CY2020Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1644211 USD
CY2019Q3 us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
1440339 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4799457 USD
us-gaap Selling General And Administrative Expense
SellingGeneralAndAdministrativeExpense
4243490 USD
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
4499023 USD
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
4259163 USD
us-gaap Operating Expenses
OperatingExpenses
12835682 USD
us-gaap Operating Expenses
OperatingExpenses
12541253 USD
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4362622 USD
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-4207476 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12588944 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-12389198 USD
CY2020Q3 us-gaap Interest Income Operating
InterestIncomeOperating
15864 USD
CY2019Q3 us-gaap Interest Income Operating
InterestIncomeOperating
53700 USD
us-gaap Interest Income Operating
InterestIncomeOperating
67358 USD
us-gaap Interest Income Operating
InterestIncomeOperating
188204 USD
CY2020Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-144035 USD
CY2019Q3 us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
13330 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-186072 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
27359 USD
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-5738 USD
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1103 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1967 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
2012 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4496531 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-4141549 USD
us-gaap Net Income Loss
NetIncomeLoss
-12709625 USD
us-gaap Net Income Loss
NetIncomeLoss
-12171623 USD
CY2020Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6060 USD
CY2019Q3 us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
6060 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18180 USD
us-gaap Preferred Stock Dividends Income Statement Impact
PreferredStockDividendsIncomeStatementImpact
18180 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4502591 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-4147609 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15994289 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12458072 USD
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.40
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23341218 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6024679 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15941665 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5180221 shares
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
7311344 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
177309 USD
CY2020Q1 crdf Sale Of Stock Value Common And Warrants Net
SaleOfStockValueCommonAndWarrantsNet
-1000001 USD
CY2020Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1456369 USD
CY2020Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2020Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
293017 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4088562 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
6143418 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
281776 USD
CY2020Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-7500 USD
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
17278428 USD
CY2020Q2 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
4605017 USD
CY2020Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2020Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
213492 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-4124532 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
24384039 USD
CY2020Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
361884 USD
CY2020Q3 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
12910802 USD
CY2020Q3 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
6832 USD
CY2020Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2020Q3 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
361584 USD
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-4496531 USD
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
33522550 USD
CY2020Q2 crdf Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment
CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
616143 USD
CY2020Q2 crdf Warrants Fair Value
WarrantsFairValue
370666 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
10084192 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
200067 USD
CY2019Q1 crdf Costof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment
CostofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
40000 USD
CY2019Q1 crdf Discountof Issuanceof Common Stock Preferred Stockand Warrantsfor Clinical Trial Funding Commitment
DiscountofIssuanceofCommonStockPreferredStockandWarrantsforClinicalTrialFundingCommitment
235640 USD
CY2019Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
-40000 USD
CY2019Q1 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
3282266 USD
CY2019Q1 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2019Q1 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
70487 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3904771 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
9686181 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
148834 USD
CY2019Q2 crdf Sale Of Stock Value Common And Warrants Net
SaleOfStockValueCommonAndWarrantsNet
-2902740 USD
CY2019Q2 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
1564 USD
CY2019Q2 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2019Q2 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
240279 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-4125303 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
8848235 USD
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
266325 USD
CY2019Q3 crdf Sale Of Stock Value Common And Warrants Net
SaleOfStockValueCommonAndWarrantsNet
-1483581 USD
CY2019Q3 crdf Stock Issued During Period Value Warrants Exercised
StockIssuedDuringPeriodValueWarrantsExercised
7180 USD
CY2019Q3 us-gaap Dividends Preferred Stock
DividendsPreferredStock
6060 USD
CY2019Q3 crdf Release Of Clinical Trial Funding Commitment
ReleaseOfClinicalTrialFundingCommitment
198268 USD
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-4141549 USD
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
6655980 USD
us-gaap Net Income Loss
NetIncomeLoss
-12709625 USD
us-gaap Net Income Loss
NetIncomeLoss
-12171623 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
34169 USD
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
348748 USD
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
372828 USD
us-gaap Share Based Compensation
ShareBasedCompensation
820969 USD
us-gaap Share Based Compensation
ShareBasedCompensation
615226 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
-186072 USD
us-gaap Unrealized Gain Loss On Derivatives
UnrealizedGainLossOnDerivatives
27359 USD
crdf Releaseofclinicaltrialfundingcommitmentforservicesreceived
Releaseofclinicaltrialfundingcommitmentforservicesreceived
868093 USD
crdf Releaseofclinicaltrialfundingcommitmentforservicesreceived
Releaseofclinicaltrialfundingcommitmentforservicesreceived
509034 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-1806 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
68145 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
886 USD
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-15717 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
623902 USD
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-277876 USD
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-240086 USD
crdf Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-224400 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
318991 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
837551 USD
crdf Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-635630 USD
crdf Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-576141 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
-39916 USD
us-gaap Increase Decrease In Other Operating Liabilities
IncreaseDecreaseInOtherOperatingLiabilities
0 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-11191025 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9990636 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
153784 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
67622 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-153784 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-67622 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
633807 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
97260 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
18278429 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4386321 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-7500 USD
us-gaap Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
-40000 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
6832 USD
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
18972188 USD
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
3291010 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
305000 USD
us-gaap Proceeds From Issuance Of Long Term Debt
ProceedsFromIssuanceOfLongTermDebt
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
37554949 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
7637331 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
26210140 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-2420927 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
10195292 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
11453133 USD
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
36405432 USD
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9032206 USD
crdf Lessee Operating Lease Number Of Renewal Options
LesseeOperatingLeaseNumberOfRenewalOptions
1 renewal_option
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
36400000 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
800 USD
us-gaap Income Taxes Paid
IncomeTaxesPaid
800 USD
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
18180 USD
crdf Preferred Stock Dividend Accrued
PreferredStockDividendAccrued
18180 USD
CY2020Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4502591 USD
CY2019Q3 us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-4147609 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-15994289 USD
us-gaap Net Income Loss Available To Common Stockholders Diluted
NetIncomeLossAvailableToCommonStockholdersDiluted
-12458072 USD
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23341218 shares
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6024679 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
15941665 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5180221 shares
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.69
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.00
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.40
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
12844384 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5901540 shares
CY2020Q3 us-gaap Lease Cost
LeaseCost
26015 USD
CY2020Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3635900 USD
CY2019Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
3482116 USD
CY2020Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2953041 USD
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
2604293 USD
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
682859 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
877823 USD
crdf Lessor Number Of Subleases
LessorNumberOfSubleases
3 lease
crdf Lessee Operating Lease Monthly Rent Payment
LesseeOperatingLeaseMonthlyRentPayment
78000 USD
crdf Lessee Operating Lease Annual Rent Increase Percentage
LesseeOperatingLeaseAnnualRentIncreasePercentage
0.03
us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
34169 USD
CY2020Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
crdf Lessee Operating Lease Annual Rent Increase Percentage
LesseeOperatingLeaseAnnualRentIncreasePercentage
0.03
crdf Lessor Number Of Subleases
LessorNumberOfSubleases
3 lease
CY2020Q3 us-gaap Operating Lease Impairment Loss
OperatingLeaseImpairmentLoss
0 USD
CY2020Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
98808 USD
CY2019Q3 us-gaap Operating Lease Cost
OperatingLeaseCost
191472 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
344836 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
578919 USD
CY2020Q3 us-gaap Sublease Income
SubleaseIncome
72793 USD
CY2019Q3 us-gaap Sublease Income
SubleaseIncome
99937 USD
us-gaap Sublease Income
SubleaseIncome
218380 USD
us-gaap Sublease Income
SubleaseIncome
299812 USD
CY2019Q3 us-gaap Lease Cost
LeaseCost
91535 USD
us-gaap Lease Cost
LeaseCost
126456 USD
us-gaap Lease Cost
LeaseCost
279107 USD
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
423163 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
697418 USD
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
883534 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
865379 USD
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
207178 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
860963 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1090712 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
1726342 USD
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y3M18D
CY2019Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2019Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.065
CY2020Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
236748 USD
CY2019Q3 us-gaap Operating Lease Payments
OperatingLeasePayments
229927 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
706211 USD
us-gaap Operating Lease Payments
OperatingLeasePayments
685865 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
159167 USD
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Remainder Of Fiscal Year
LessorOperatingLeasePaymentsToBeReceivedRemainderOfFiscalYear
72793 USD
CY2020Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeRemainderOfFiscalYear
86374 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
968165 USD
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Next Twelve Months
LessorOperatingLeasePaymentsToBeReceivedNextTwelveMonths
403345 USD
CY2020Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year One
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearOne
564820 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
5868 USD
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Two Years
LessorOperatingLeasePaymentsToBeReceivedTwoYears
0 USD
CY2020Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Two
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearTwo
5868 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
3423 USD
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received Three Years
LessorOperatingLeasePaymentsToBeReceivedThreeYears
0 USD
CY2020Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due Year Three
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDueYearThree
3423 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
1136623 USD
CY2020Q3 us-gaap Lessor Operating Lease Payments To Be Received
LessorOperatingLeasePaymentsToBeReceived
476138 USD
CY2020Q3 crdf Lessee Operating Lease Liability Payments Net Of Sublease Income Due
LesseeOperatingLeaseLiabilityPaymentsNetOfSubleaseIncomeDue
660485 USD
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
45911 USD
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
1090712 USD
CY2020Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
361884 USD
CY2019Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
266325 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
820969 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
615226 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
770582 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
321870 USD
crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Granted
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsGranted
1.70
crdf Class Of Warrant Or Right Number Exercised
ClassOfWarrantOrRightNumberExercised
9047582 shares
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
10589482 shares
CY2019Q4 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
4.08
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P3Y8M12D
crdf Class Of Warrant Or Right Number Granted
ClassOfWarrantOrRightNumberGranted
5831451 shares
crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights Exercised
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRightsExercised
2.17
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
7373351 shares
CY2020Q3 crdf Class Of Warrant Or Right Weighted Average Exercise Price Of Warrants Or Rights
ClassOfWarrantOrRightWeightedAverageExercisePriceOfWarrantsOrRights
4.54
crdf Class Of Warrant Or Right Term Of Outstanding Warrants Or Rights
ClassOfWarrantOrRightTermOfOutstandingWarrantsOrRights
P4Y3M18D
CY2019Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
333333 shares
CY2019Q1 crdf Servicereceivable
Servicereceivable
1675000 USD
CY2020Q2 us-gaap Conversion Of Stock Shares Issued1
ConversionOfStockSharesIssued1
1546700 shares
CY2020Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
2213115 shares
CY2020Q2 crdf Deemed Dividend Related To Beneficial Conversion Feature Of Preferred Stock
DeemedDividendRelatedToBeneficialConversionFeatureOfPreferredStock
2700000 USD
CY2020Q2 crdf Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
184426 shares
CY2020Q2 crdf Class Of Warrant Or Right Months Until Exercisable
ClassOfWarrantOrRightMonthsUntilExercisable
P6M
CY2020Q2 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
3.05
CY2020Q2 crdf Class Of Warrant Or Right Expiration Term
ClassOfWarrantOrRightExpirationTerm
P5Y6M
CY2020Q2 crdf Warrants Fair Value
WarrantsFairValue
370666 USD
CY2020Q1 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
800000 shares
CY2020Q1 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
1000000.0 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
904970 shares
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
1100000 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
447761 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.34
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
146854 shares
CY2020Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
1.43
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
810000 USD
CY2020Q2 us-gaap Sale Of Stock Number Of Shares Issued In Transaction
SaleOfStockNumberOfSharesIssuedInTransaction
1205400 shares
CY2020Q2 us-gaap Sale Of Stock Consideration Received On Transaction
SaleOfStockConsiderationReceivedOnTransaction
2500000 USD

Files In Submission

Name View Source Status
0001628280-20-015726-index-headers.html Edgar Link pending
0001628280-20-015726-index.html Edgar Link pending
0001628280-20-015726.txt Edgar Link pending
0001628280-20-015726-xbrl.zip Edgar Link pending
crdf-093020exhibit311.htm Edgar Link pending
crdf-093020exhibit312.htm Edgar Link pending
crdf-093020exhibit321.htm Edgar Link pending
crdf-093020exhibit322.htm Edgar Link pending
crdf-20200930.htm Edgar Link pending
crdf-20200930.xsd Edgar Link pending
crdf-20200930_cal.xml Edgar Link unprocessable
crdf-20200930_def.xml Edgar Link unprocessable
crdf-20200930_htm.xml Edgar Link completed
crdf-20200930_lab.xml Edgar Link unprocessable
crdf-20200930_pre.xml Edgar Link unprocessable
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending